This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Technology Companies: Maxlinear (MXL) and Cellebrite DI (CLBT)

Tipranks - Sat Apr 18, 8:24AM CDT

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Maxlinear (MXL) and Cellebrite DI (CLBT) with bullish sentiments.

Claim 30% Off TipRanks

Maxlinear (MXL)

In a report released today, Richard Shannon from Craig-Hallum maintained a Buy rating on Maxlinear. The company’s shares closed last Thursday at $23.35.

According to TipRanks.com, Shannon is a top 25 analyst with an average return of 76.2% and a 61.1% success rate. Shannon covers the Technology sector, focusing on stocks such as MACOM Technology Solutions Holdings, Credo Technology Group Holding Ltd, and Lightpath Technologies. ;'>

Currently, the analyst consensus on Maxlinear is a Moderate Buy with an average price target of $22.08, which is a -0.6% downside from current levels. In a report issued on April 13, TipRanks – Google also upgraded the stock to Buy with a $23.50 price target.

See the top stocks recommended by analysts >>

Cellebrite DI (CLBT)

Craig-Hallum analyst Jeff Van Rhee maintained a Buy rating on Cellebrite DI today. The company’s shares closed last Thursday at $12.71, close to its 52-week low of $10.25.

According to TipRanks.com, Rhee is a 5-star analyst with an average return of 25.6% and a 51.2% success rate. Rhee covers the Technology sector, focusing on stocks such as Intellicheck Mobilisia, Frequency Electronics, and Alkami Technology. ;'>

Cellebrite DI has an analyst consensus of Strong Buy, with a price target consensus of $20.67, which is a 59.0% upside from current levels. In a report issued on April 15, William Blair also maintained a Buy rating on the stock.

Read More on MXL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.